Myriad Genetics CFO Bryan Riggsbee retires; Scott Leffler named successor effective Jan 29, 2024

MYRIAD GENETICS INC

Riggsbee steps down as CFO by Jan 31, 2024; will serve as strategic advisor through March 31, 2024.
New CFO Scott Leffler appointed effective Jan 29, 2024; previously CFO at Clover Health and Sotera Health.
Leffler receives base salary $550k, target bonus 75%, sign-on bonus $400k, and initial RSU grants totaling $2.5M.
Company reiterates 2023 and 2024 financial guidance previously issued on Nov 6, 2023.
Departure not due to disagreements; separation includes consulting fee $2,713.65/week and continued equity vesting.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

R. Bryan Riggsbee

Chief Financial Officer

MYGN · MYRIAD GENETICS INC

Effective: 2024-01-29
Successor: Scott J. Leffler
Filed: December 21, 2023, 6:59 PM ET

On December 15, 2023, R. Bryan Riggsbee, Chief Financial Officer and principal financial officer of Myriad Genetics, Inc. (the “Company”) and the Company mutually reached an agreement that Mr. Riggsbee would step down from such position, effective upon the earlier of (1) the date that a new Chief Financial Officer and principal financial officer commences his or her employment at the Company and (2) January 31, 2024.

Appointed

Scott J. Leffler

Chief Financial Officer

MYGN · MYRIAD GENETICS INC

Effective: 2024-01-29
Filed: December 21, 2023, 6:59 PM ET

On December 15, 2023, the Board appointed Scott J. Leffler (“Mr. Leffler”) as the Company's Chief Financial Officer and principal financial officer, effective as of his first date of employment, January 29, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

R. Bryan Riggsbee departed as Chief Financial Officer at MYRIAD GENETICS INC.

Action: stepped down
Role: Chief Financial Officer

Exact text from the filing

On December 15, 2023, R. Bryan Riggsbee, Chief Financial Officer and principal financial officer of Myriad Genetics, Inc. (the “Company”) and the Company mutually reached an agreement that Mr. Riggsbee would step down from such position, effective upon the earlier of (1) the date that a new Chief Financial Officer and principal financial officer commences his or her employment at the Company and (2) January 31, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott J. Leffler was appointed as Chief Financial Officer at MYRIAD GENETICS INC.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On December 15, 2023, the Board appointed Scott J. Leffler (“Mr. Leffler”) as the Company's Chief Financial Officer and principal financial officer, effective as of his first date of employment, January 29, 2024.

View on SEC.gov

MYRIAD GENETICS INC filing history →

Source: SEC EDGAR

accession 0000899923-23-000117

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.